The agreement allows Actavis and its partner Egis Pharmaceuticals, to begin selling a generic copy of Crestor in May 2016, and Actavis will have to pay AstraZeneca a 39 percent royalty on net sales until the end of pediatric exclusivity in July 2016 ( read here).

FORBES: AstraZeneca & A Pay-To-Delay Deal The FTC Would Not Like